ArticleJBMR plus2026
The therapeutic window: timing dentoalveolar surgery to minimize MRONJ risk in denosumab-treated osteoporotic patients.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis patients treated with denosumab (Dmab) remain at risk for medication-related osteonecrosis of the jaw (MRONJ), particularly after dentoalveolar surgery. Optimizing surgical timing may reduce this risk while avoiding complications related to prolonged drug interruption. This retrospective cohort study evaluated 258 osteoporotic patients receiving Dmab and examined both patient-level data and intervention-level data from 91 patients who underwent 185 dentoalveolar procedures. Multivariable logistic regression and generalized estimating equations (GEE) were applied to identify factors associated with MRONJ development. Medication-related osteonecrosis of the jaw occurred in 5.43% of the total cohort. All MRONJ cases at the intervention level were observed when dentoalveolar procedures were performed within 3 mo of a Dmab injection. A longer interval between the last Dmab dose and dentoalveolar intervention demonstrated a strong protective effect against MRONJ (OR 0.35,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.